These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 10831691

  • 1. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
    Petersein J, Spinazzi A, Giovagnoni A, Soyer P, Terrier F, Lencioni R, Bartolozzi C, Grazioli L, Chiesa A, Manfredi R, Marano P, Van Persijn Van Meerten EL, Bloem JL, Petre C, Marchal G, Greco A, McNamara MT, Heuck A, Reiser M, Laniado M, Claussen C, Daldrup HE, Rummeny E, Kirchin MA, Pirovano G, Hamm B.
    Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G, Altmeyer K, Kirchin MA, Seidel R, Grazioli L, Morana G, Saini S.
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [Abstract] [Full Text] [Related]

  • 3. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB.
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
    Zhang HM, Ouyang H, Zhou CW.
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
    [Abstract] [Full Text] [Related]

  • 5. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.
    Caudana R, Morana G, Pirovano GP, Nicoli N, Portuese A, Spinazzi A, Di Rito R, Pistolesi GF.
    Radiology; 1996 May; 199(2):513-20. PubMed ID: 8668804
    [Abstract] [Full Text] [Related]

  • 6. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM, Lee C, Williams NM.
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
    Pirovano G, Vanzulli A, Marti-Bonmati L, Grazioli L, Manfredi R, Greco A, Holzknecht N, Daldrup-Link HE, Rummeny E, Hamm B, Arneson V, Imperatori L, Kirchin MA, Spinazzi A.
    AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
    [Abstract] [Full Text] [Related]

  • 8. Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.
    Peña CS, Saini S, Baron RL, Hamm BA, Morana G, Caudana R, Giovagnoni A, Villa A, Carriero A, Mathieu D, Bourne MW, Kirchin MA, Pirovano G, Spinazzi A.
    Korean J Radiol; 2001 Oct; 2(4):210-5. PubMed ID: 11754328
    [Abstract] [Full Text] [Related]

  • 9. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
    Grazioli L, Morana G, Kirchin MA, Schneider G.
    Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
    [Abstract] [Full Text] [Related]

  • 10. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
    Schneider G, Maas R, Schultze Kool L, Rummeny E, Gehl HB, Lodemann KP, Kirchin MA.
    Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
    [Abstract] [Full Text] [Related]

  • 11. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV, Bourne MW, Sardanelli F, Wasser MN, Bonomo L, Boetes C, Müller-Schimpfle M, Hall-Craggs MA, Hamm B, Orlacchio A, Bartolozzi C, Kessler M, Fischer U, Schneider G, Oudkerk M, Teh WL, Gehl HB, Salerio I, Pirovano G, La Noce A, Kirchin MA, Spinazzi A.
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [Abstract] [Full Text] [Related]

  • 12. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
    Grazioli L, Morana G, Caudana R, Benetti A, Portolani N, Talamini G, Colombari R, Pirovano G, Kirchin MA, Spinazzi A.
    Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
    Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, Casalino DD, Davis PL, Francis IR, Krinsky G, Lee FT, Lu D, Paulson EK, Schwartz LH, Siegelman ES, Small WC, Weber TM, Welber A, Shamsi K.
    Radiology; 2005 Oct; 237(1):89-98. PubMed ID: 16126918
    [Abstract] [Full Text] [Related]

  • 14. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E, Pizzolato R, De Paoli L, Angileri R, Ukmar M, Cova MA.
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [Abstract] [Full Text] [Related]

  • 15. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
    Grazioli L, Morana G, Federle MP, Brancatelli G, Testoni M, Kirchin MA, Menni K, Olivetti L, Nicoli N, Procacci C.
    Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669
    [Abstract] [Full Text] [Related]

  • 16. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.
    Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ, Strotzer M, Taupitz M, Vogl TJ, European EOB Study Group.
    Radiology; 2004 Jan; 230(1):266-75. PubMed ID: 14695400
    [Abstract] [Full Text] [Related]

  • 17. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
    del Frate C, Bazzocchi M, Mortele KJ, Zuiani C, Londero V, Como G, Zanardi R, Ros PR.
    Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
    [Abstract] [Full Text] [Related]

  • 18. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC, Inan N, Anik Y, Erturk MS, Ural D, Demirci A.
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [Abstract] [Full Text] [Related]

  • 19. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM, Wells JW, Williams NM.
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [Abstract] [Full Text] [Related]

  • 20. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU, Reiser MF, Huber AM.
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.